AR100894A1 - Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa - Google Patents
Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasaInfo
- Publication number
- AR100894A1 AR100894A1 ARP150101940A ARP150101940A AR100894A1 AR 100894 A1 AR100894 A1 AR 100894A1 AR P150101940 A ARP150101940 A AR P150101940A AR P150101940 A ARP150101940 A AR P150101940A AR 100894 A1 AR100894 A1 AR 100894A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- substituents
- cycloalkyl
- heteroaryl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract 7
- -1 nitro, hydroxy Chemical group 0.000 abstract 7
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 102000001556 1-Phosphatidylinositol 4-Kinase Human genes 0.000 abstract 1
- 108010029190 1-Phosphatidylinositol 4-Kinase Proteins 0.000 abstract 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Estos compuestos son inhibidores selectivos de actividad IIIb de Fosfatidilinositol-4-quinasa (PI4KIIIb), son beneficiosos en el tratamiento y/o prevención de diversas dolencias humanas, que incluyen trastornos inflamatorios, autoinmunes u oncológicos; enfermedades virales y malaria; y el rechazo de trasplante de órganos o células. Reivindicación 1: Un compuesto de fórmula (1) ó (2) o un N-óxido del mismo, o una sal o solvato aceptable para el uso farmacéutico del mismo, caracterizado porque X representa N o CH; T representa N o C-R²; U representa oxígeno, azufre o N-R⁴; Q representa un resto del grupo de fórmulas (3), en las que el asterisco (*) representa el punto de unión al resto de la molécula; V representa -CH₂-, -C(CH₃)₂-, -CH₂CH₂- o -CH₂CH₂CH₂-; W representa el residuo de un grupo cicloalquilo C₃₋₇; Y representa un enlace covalente, o un grupo enlazador seleccionado de -C(O)-, -S(O)-, -S(O)₂-, -C(O)O-, -C(O)N(R⁵)-, -C(O)C(O)- y -S(O)₂N(R⁵)-, o un grupo enlazador de fórmula (4), en la que el asterisco (*) representa el punto de unión al resto de la molécula; Z representa hidrógeno; o Z representa alquilo C₁₋₆, alquenilo C₂₋₆, cicloalquilo C₃₋₇, cicloalquilo C₃₋₇alquilo C₁₋₆, heterocicloalquilo C₃₋₇, heterocicloalquilo C₃₋₇alquilo C₁₋₆, arilo, arilalquilo C₁₋₆, heteroarilo o heteroarilalquilo C₁₋₆, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; A¹ representa hidrógeno, ciano o trifluorometilo; o A¹ representa alquilo C₁₋₆, sustituido en forma opcional por uno o más sustituyentes seleccionados en forma independiente de flúor, -ORᵃ, trifluorometoxi, -NRᵇRᶜ, -CO₂Rᵈ y -CONRᵇRᶜ; o A¹ representa cicloalquilo C₃₋₇; A² representa hidrógeno o alquilo C₁₋₆; R¹ y R² representan en forma independiente hidrógeno, halógeno, ciano, nitro, hidroxi, trifluorometilo, trifluorometoxi, -ORᵃ, -SRᵃ, -SORᵃ, -SO₂Rᵃ, NRᵇRᶜ, -CH₂NRᵇRᶜ, -NRᶜCORᵈ, -CH₂NRᶜCORᵈ, -NRᶜCO₂Rᵈ, -NHCONRᵇRᶜ, -NRᶜSO₂Rᵉ, -N(SO₂Rᵉ)₂, -NHSO₂NRᵇRᶜ, -CORᵈ, -CO₂Rᵈ, -CONRᵇRᶜ, -CON(ORᵃ)Rᵇ o -SO₂NRᵇRᶜ; o alquilo C₁₋₆, cicloalquilo C₃₋₇, cicloalquilo C₃₋₇alquilo C₁₋₆, arilo, arilalquilo C₁₋₆, heterocicloalquilo C₃₋₇, heterocicloalquilo C₃₋₇alquilo C₁₋₆, heterocicloalquenilo C₃₋₇, heteroarilo o heteroarilalquilo C₁₋₆, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; R³ representa hidrógeno, halógeno o alquilo C₁₋₆; R⁴ representa hidrógeno; o R⁴ representa alquilo C₁₋₆, arilo, arilalquilo C₁₋₆, heteroarilo o heteroarilalquilo C₁₋₆, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; R⁵ representa hidrógeno; o R⁵ representa alquilo C₁₋₆, sustituido en forma opcional por uno o más sustituyentes seleccionados en forma independiente de -ORᵃ y -NRᵇRᶜ; Rᵃ representa hidrógeno; o Rᵃ representa alquilo C₁₋₆, arilo, arilalquilo C₁₋₆, heteroarilo o heteroarilalquilo C₁₋₆, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; Rᵇ y Rᶜ representan en forma independiente hidrógeno o trifluorometilo; o alquilo C₁₋₆; cicloalquilo C₃₋₇, cicloalquilo C₃₋₇alquilo C₁₋₆, arilo, arilalquilo C₁₋₆, heterocicloalquilo C₃₋₇, heterocicloalquilo C₃₋₇alquilo C₁₋₆, heteroarilo o heteroarilalquilo C₁₋₆, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; o Rᵇ y Rᶜ, cuando se toman conjuntamente con el átomo de nitrógeno al que ambos están unidos, representan azetidin-1-ilo, pirrolidin-1-ilo, oxazolidin-3-ilo, isoxazolidin-2-ilo, tiazolidin-3-ilo, isotiazolidin-2-ilo, piperidin-1-ilo, morfolin-4-ilo, tiomorfolin-4-ilo, piperazin-1-ilo homopiperidin-1-ilo homomorfolin-4-ilo o homopiperazin-1-ilo, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; Rᵈ representa hidrógeno; o alquilo C₁₋₆, cicloalquilo C₃₋₇, arilo, heterocicloalquilo C₃₋₇ o heteroarilo, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; y Rᵉ representa alquilo C₁₋₆, arilo o heteroarilo, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1410816.1A GB201410816D0 (en) | 2014-06-17 | 2014-06-17 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100894A1 true AR100894A1 (es) | 2016-11-09 |
Family
ID=51266752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101940A AR100894A1 (es) | 2014-06-17 | 2015-06-17 | Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9969748B2 (es) |
| EP (1) | EP3157923A1 (es) |
| JP (1) | JP2017518384A (es) |
| CN (1) | CN106507674A (es) |
| AR (1) | AR100894A1 (es) |
| BR (1) | BR112016029630A2 (es) |
| CA (1) | CA2950672A1 (es) |
| GB (1) | GB201410816D0 (es) |
| RU (1) | RU2017101324A (es) |
| TW (1) | TW201625628A (es) |
| UY (1) | UY36171A (es) |
| WO (1) | WO2015193168A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017004133A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| GB201517263D0 (en) | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| GB201521767D0 (en) | 2015-12-10 | 2016-01-27 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D | Therapeutic agents |
| EP3419980A4 (en) | 2016-02-26 | 2019-07-03 | The Board of Trustees of the Leland Stanford Junior University | INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY |
| EP3511333B1 (en) * | 2016-11-23 | 2021-05-12 | Wuxi Fortune Pharmaceutical Co., Ltd | Crystal form and salt form of 7h-pyrrolo[2,3-d]pyrimidine compound and preparation method therefor |
| CN109721531B (zh) * | 2017-10-27 | 2022-07-29 | 中国科学院合肥物质科学研究院 | 一种新型的脂质体激酶抑制剂 |
| MX2020007521A (es) | 2018-01-17 | 2022-12-05 | Glaxosmithkline Ip Dev Ltd | Inhibidores de pi4kiii. |
| AU2019324089B2 (en) | 2018-08-21 | 2024-06-13 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic heteroaromatic ring derivative |
| JP2022527255A (ja) * | 2019-03-21 | 2022-06-01 | ザ ボード オブ トラスティス オブ ザ リーランド スタンフォード ジュニア ユニヴァーシティー | Ｐｉ４－キナーゼ阻害剤及びその使用方法 |
| CN112592354B (zh) * | 2019-07-30 | 2022-05-27 | 厦门宝太生物科技股份有限公司 | 一种异噁唑并嘧啶类杂环化合物的制备方法 |
| US20230219962A1 (en) * | 2020-06-04 | 2023-07-13 | Merck Sharp & Dohme Llc | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS |
| US20230322788A1 (en) * | 2020-08-05 | 2023-10-12 | Beigene, Ltd. | Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors |
| CN114057743A (zh) * | 2020-08-05 | 2022-02-18 | 百济神州(北京)生物科技有限公司 | 制备kras g12c抑制剂咪唑并三嗪和吡咯并嘧啶衍生物的方法 |
| WO2022067462A1 (en) * | 2020-09-29 | 2022-04-07 | Beigene (Beijing) Co., Ltd. | Process for preparing inhibitors of kras g12c |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| DE2121950A1 (en) * | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
| RO62428A (fr) * | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2008005368A2 (en) * | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
| JP2008012418A (ja) | 2006-07-05 | 2008-01-24 | Daikin Ind Ltd | プレフィルタ |
| WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| EP2022503B1 (de) | 2007-08-07 | 2011-10-19 | Symrise AG | Verkapselte Vacciniumextrakte mit ausgewogener Magen-Darm-Freisetzung |
| CA2705719C (en) * | 2007-09-14 | 2016-10-11 | Janssen Pharmaceutica N.V. | Thieno-and furo-pyrimidine modulators of the histamine h4 receptor |
| EP2621923B1 (en) * | 2010-09-29 | 2017-03-29 | Intervet International B.V. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
| MX2013003913A (es) * | 2010-10-08 | 2013-09-26 | Abbvie Inc | Compuestos de furo [3, 2-d] pirimidina. |
| GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| GB201119401D0 (en) * | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| WO2014039714A2 (en) * | 2012-09-06 | 2014-03-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
-
2014
- 2014-06-17 GB GBGB1410816.1A patent/GB201410816D0/en not_active Ceased
-
2015
- 2015-06-11 BR BR112016029630A patent/BR112016029630A2/pt not_active IP Right Cessation
- 2015-06-11 RU RU2017101324A patent/RU2017101324A/ru not_active Application Discontinuation
- 2015-06-11 EP EP15727999.3A patent/EP3157923A1/en not_active Withdrawn
- 2015-06-11 US US15/318,422 patent/US9969748B2/en not_active Expired - Fee Related
- 2015-06-11 CN CN201580032335.4A patent/CN106507674A/zh active Pending
- 2015-06-11 WO PCT/EP2015/063051 patent/WO2015193168A1/en active Application Filing
- 2015-06-11 CA CA2950672A patent/CA2950672A1/en not_active Abandoned
- 2015-06-11 JP JP2017518423A patent/JP2017518384A/ja active Pending
- 2015-06-15 TW TW104119305A patent/TW201625628A/zh unknown
- 2015-06-16 UY UY0001036171A patent/UY36171A/es not_active Application Discontinuation
- 2015-06-17 AR ARP150101940A patent/AR100894A1/es unknown
-
2018
- 2018-03-16 US US15/924,020 patent/US20180201622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016029630A2 (pt) | 2017-08-22 |
| TW201625628A (zh) | 2016-07-16 |
| US9969748B2 (en) | 2018-05-15 |
| EP3157923A1 (en) | 2017-04-26 |
| RU2017101324A3 (es) | 2018-12-27 |
| CN106507674A (zh) | 2017-03-15 |
| JP2017518384A (ja) | 2017-07-06 |
| CA2950672A1 (en) | 2015-12-23 |
| GB201410816D0 (en) | 2014-07-30 |
| UY36171A (es) | 2016-01-29 |
| RU2017101324A (ru) | 2018-07-17 |
| US20180201622A1 (en) | 2018-07-19 |
| WO2015193168A1 (en) | 2015-12-23 |
| US20170129905A1 (en) | 2017-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100894A1 (es) | Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa | |
| ECSP16076566A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4 | |
| CY1122933T1 (el) | Ενωσεις θειαζολοκαρβοξαμιδιων και πυριδινοκαρβοξαμιδιου χρησιμες ως αναστολεις κινασης ριμ | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR096330A1 (es) | Derivados del bipirazol como inhibidores jak | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| PE20170144A1 (es) | 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| AR100984A1 (es) | Método para producir un compuesto heterocíclico fusionado | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR103265A1 (es) | Compuestos de azolina sustituidos con un sistema de anillos condensado | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| AR098337A1 (es) | Triazolopirazina | |
| AR077417A1 (es) | Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa o agente inductor de la produccion de eritropoyetina | |
| AR090587A1 (es) | Compuestos triciclicos sustituidos con actividad hacia los receptores ep1 | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| PE20161366A1 (es) | Heterociclil-sulfonas sustituidas con heteroarilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |